Published in Healthcare Finance, Tax and Law Weekly, December 20th, 2006
The presentation was authored by scientists from DelSite Biotechnologies, Inc., with contributions from scientists from Texas A&M University and the National Cancer Institute (NCI), and showed that the GelVac powder formulation developed for nasal application can also be injected after reconstituted, with enhanced immune response.
Data showed that the GelVac vaccine formulations...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Finance, Tax and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.